Michael S. Weiss, executive chairman and chief executive officer, said, “We are extremely pleased to welcome Adam to the TG Therapeutics team. He brings extensive experience to the company and as we move towards commercialization he will be an invaluable member of the team.  I look forward to working with him and driving towards our goal of bringing novel combination treatment options to patients with B-cell malignancies.”

Adam Waldman said, “I am thrilled to be joining TG Therapeutics with the opportunity to build a world class commercial team and to launch multiple new products over the next few years. TG has a unique patient centered approach and several promising late stage assets addressing high unmet needs.”

Mr. Waldman joins TG Therapeutics with more than 20 years of experience in the biotechnology and life science industries.